Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma
This study established CD133<sup>+</sup> CSCs as critical mediators through the CD133-MYH9/β-catenin axis in MASLD-HCC. Targeting CD133 enhances multikinase inhibitor efficacy, offering a promising therapeutic strategy for MASLD-HCC.
Authors
- Huarong Chen (ORCID: https://orcid.org/0000-0002-8598-3899)
- Kai Yuan (ORCID: https://orcid.org/0000-0002-4777-4076)
- Pingmei Huang (ORCID: https://orcid.org/0000-0002-4893-8159)
- Qinyao Wei (ORCID: https://orcid.org/0009-0006-7809-3384)
- D.M. Chen (ORCID: https://orcid.org/0009-0005-8376-9003)
- Ma Stephanie
- Xingyu Zhou (ORCID: https://orcid.org/0000-0001-6714-8227)
- Yasi Pan
- C. L. Liang
- Yanqiang Ding
- Jun Yu
- Chi Chun Wong
- Ka Fai To
- Lina Wang
- Xiang Zhang
- Terence Kin-Wah Lee
- Harry Cheuk Hay Lau
- Alvin Ho Kwan Cheung
Institutions
- Hong Kong Polytechnic University (HK)
- Sun Yat-sen University (CN)
- Chinese University of Hong Kong (HK)
- Chinese University of Hong Kong, Shenzhen (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Gut
- Published
- 2025-12-25
- DOI
- https://doi.org/10.1136/gutjnl-2025-336527
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.00